5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

Overview of attention for article published in Blood, February 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 34 news outlets
blogs: 1 blog
policy: 1 policy source

twitter: 13 X users
guideline: 6 clinical guideline sources
seminars: 1 seminar series

Readers on

mendeley: 343 Mendeley

So far, Altmetric has seen 13 X posts from 13 X users, with an upper bound of 88,632 followers.

@owl_poster @DdelAlamo More recent, and not super-duper blockbuster, but in CAR-T Yescarta (~1.8B/yr) was approved 3 months after Kymriah (~500M/yr). Yescarta does appear to be the better drug (they're using words like "curative" in connection to cancer…

RT @Transplant_Doc: 5-year F/U of ZUMA-1 trial (axi-cel) in refractory large B-cell lymphoma. Median OS: 25.8 months, 5-year OS: 42.6%. Po…

as summarized in https://t.co/CYQYsCdKA1 https://t.co/gPL7hPi43K

@SuyogCancer @NatRevClinOncol For DLBCL Five year update of ZUMA-1 (may 2023), just after above publication. https://t.co/kY9h7viUhi

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 9 additional X posts.